Trial Information
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Inclusion Criteria:
- pathologic confirmation of prostate cancer
- patients who are taking LHRH antagonist or anti- androgen or both of them within 6
months since starting.
Exclusion Criteria:
- patients who are hard to be analysed by limitation of chart record according to
investigators'discretion
- patients who already have been registered in this study
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.
Principal Investigator
Joon Woo Bahn, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca Korea
Authority:
Korea: Food and Drug Administration
Study ID:
NIS-OKR-CAS-2009/1
NCT ID:
NCT01025479
Start Date:
November 2009
Completion Date:
March 2010
Related Keywords:
- Prostate Cancer
- Osteoporosis
- Osteoporosis
- Prostate cancer
- LHRH agonist and/or anti-androgen agent
- Korean prostate cancer
- Osteoporosis
- Prostatic Neoplasms